In 2021, the IWI among MRBCs varied nearly twenty-fold, ranging from 250.5 billion yuan to 5152.9 billion yuan (see Fig. 1a). This significant gap highlighted substantial inequality in inclusive wealth distribution. To further examine regional inequality by capital structure, three...

Safi Biotherapeutics collaborates with Functional Fluidics to ensure the health and quality of manufactured red blood cells for sickle cell disease treatment.

Collaboration to support Safi IND data package for use of mRBCs in sickle cell disease chronic transfusions CAMBRIDGE, Mass. and DETROIT, July 16, 2025 /PRNewswire/ -- Safi Biotherapeutics (Safi), a biotechnology company producing stem-cell derived, manufactured human red blood cell...